Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06281977 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

A Phase 3 study, sponsored by Ottawa Heart Institute Research Corporation.

Recruiting
Registry status
Phase 3
Development phase
192
Enrollment target

NCT06281977: Recruiting Phase 3 study, sponsored by Ottawa Heart Institute Research Corporation.

NCT06281977 is a Phase 3 study that is actively recruiting participants, run by Ottawa Heart Institute Research Corporation. The registered enrollment target is 192 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06281977, a Phase 3 study, is actively recruiting participants, sponsored by Ottawa Heart Institute Research Corporation.

RECRUITING
Registry status
Phase 3
Development phase
192 participants
Enrollment target

Study Summary

The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.

Primary Outcome

Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

Interventions

  • DRUG Normal saline
  • DRUG Dexmedetomidine

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2024-05-08
Est. Completion 2027-08-01
Phase Phase 3

What NCT06281977 shows while recruiting

NCT06281977 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.

NCT06281977 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06281977 about?

NCT06281977 is a clinical study titled "Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm". The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomi...

What is the current status of trial NCT06281977?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2024-05-08. Estimated completion is 2027-08-01.

What interventions are being tested in trial NCT06281977?

The interventions under investigation include: Normal saline (DRUG), Dexmedetomidine (DRUG).

Who is sponsoring clinical trial NCT06281977?

This trial is sponsored by Ottawa Heart Institute Research Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06281977's enrollment target sits among peer trials

192 1398th of 2000 higher than 599 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492972 · 192 participants · Phase 3

    Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  • NCT01973881 · 192 participants

    Quantitative MRI for Myelofibrosis

  • NCT02535702 · 192 participants · NA

    Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

  • NCT03622359 · 192 participants · NA

    Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06281977, the US trial registry maintained by the National Library of Medicine. NCT06281977 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.